Table 1.
Clinicopathologic characteristics of FGFR2 translocation and non-translocation in ICCs.
| No. of patients | FGFR2 translocation (N = 9) | FGFR2 non-translocation (N = 164) | p value |
|---|---|---|---|
| Average age (year) | 57.00 (48–62) | 61.27 (34–81) | 0.054 |
| Male/female | 6/3 | 79/85 | 0.324 |
| HBV infection (+/–) | 5/4 | 45/119 | 0.123 |
| Cholangitis (+/–) | 7/2 | 123/41 | 1.000 |
| Fatty liver (+/–) | 2/7 | 29/135 | 0.664 |
| Schistosome (+/–) | 0/9 | 7/157 | 1.000 |
| Tumor numbers (n) | 3.25 (1–10) | 2.11 (1–11) | 0.467 |
| Tumor maximum dimension (cm) | 7.04 (2.8–11.5) | 5.66 (0.5–16) | 0.266 |
| Gross classification | 0.038a | ||
| MF type | 9 | 110 | |
| Non-MF type | 0 | 54 | |
| Histological classification | 0.052 | ||
| Pancreaticobiliary type | 8 | 92 | |
| Others type | 1 | 72 | |
| Differentiation (W/M/P/U) | 0/5/4/0 | 4/75/82/3 | 0.893 |
| G (0/1/2/3/4) | 2/4/1/1/1 | 16/79/52/15/2 | 0.119 |
| S (0/1/2/3/4) | 4/2/2/1/0 | 31/63/45/8/17 | 0.287 |
| T (I/II/III/IV) | 5/4/0/0 | 56/64/35/9 | 0.310 |
| Stage (I/II/III/IV) | 5/3/0/1 | 51/46/26/41 | 0.288 |
| OS (month) | 28.25 (4–53) | 45.10 (3–82) | 0.984 |
| DFS (month) | 30.48 (4–53) | 33.37 (1–82) | 0.263 |
G grade, M moderately differentiated, OS overall survival, P poorly differentiated, S stage, T tumor, U undifferentiated, W well differentiated.
aStatistically significant.